Before modern treatments, the 2-year survival was under 10% and average survival five months. Death usually resulted from uremia or respiratory failure. The revised Five-factor score is associated with 5-year mortality from<unk>  and is based on the following criteria: age greater than 65 years, cardiac symptoms, gastrointestinal involvement, chronic kidney disease, and the absence of ears, nose, and throat symptoms. With corticosteroids and cyclophosphamide, 5-year survival is over 80%. Long-term complications are common (86%), mainly chronic kidney failure, hearing loss, and deafness. The risk of relapse is increased in people with<unk>  who test positive for anti-PR3 ANCA antibodies and is higher than the relapse risk for microscopic polyangiitis. Today, medication toxicity is managed more carefully and long-term remissions are possible. Some affected individuals are able to lead relatively normal lives and remain in remission for 20+ years after treatment.
Granulomatosis with polyangiitis
Microscopic polyangiitis
Polyarteritis nodosa
Thromboangiitis obliterans
Eosinophilic granulomatosis with polyangiitis
Lupus vasculitis
Nephrogenic systemic fibrosis
Transplant glomerulopathy